Financing ·
Beta Bionics prices $150M public offering of common stock at $17.25 per share
BBNXBeta Bionics, Inc.
Beta Bionics, Inc. priced an underwritten public offering of common stock on September 15, 2026. The company sold 7,652,175 shares at $17.25 per share and issued pre-funded warrants for 1,043,484 additional shares at $17.2499 each. Gross proceeds are expected to be approximately $150.0 million before deducting underwriting discounts and offering expenses. The closing is scheduled for September 17, 2026. Underwriters were granted a 30-day option to purchase up to 1,304,348 additional shares at the public offering price less discounts. Net proceeds will be used for general corporate purposes, including commercialization of Mint, manufacturing expansion, research and development, clinical development, product enhancements, strategic opportunities, and working capital. Beta Bionics is a medical device company that designs and commercializes adaptive closed-loop insulin delivery systems for people with diabetes.